ArticlePregnancy (Hoboken, N.J.)2025
Inhaled insulin in pregnancy: A case series supporting feasibility and clinical potential for pregnant people with diabetes.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revolutionizing Diabetes Care: From Tech to Therapeutics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dose conversions, dose titration, and efficacy of inhaled insulin (TI) compared to rapid-acting insulin (RAA) have not been studied in pregnancy. This case series demonstrates the various management approaches of TI use in pregnant patients with preexisting diabetes. Minimal data are available on the use of TI in pregnancy. Given the scarcity of data in pregnancy, our objective was to describe approaches of TI use in diabetes management during pregnancy. Research design and methods: Case series. Results: This case series demonstrates the versatility of TI use in pregnancy, including routine meal coverage, postprandial hyperglycemia corrections, and as a feasible alternative to RAA when compliance or consistency of use with subcutaneous injections is a challenge. In this limited case series, TI appears to be a safe alternative to RAA in pregnancy. Conclusions: TI appears to be a feasible and acceptable alternative to RAA in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.